| Company | Role | Class | Num Shares | Value | Price $ | Report Date | Ownership |
|---|---|---|---|---|---|---|---|
| Tango Therapeutics, Inc. | Chief Financial Officer | Common Stock | 184,297 | $2,376,896 | $12.90 | 03 Feb 2026 | Direct |
| Blueprint Medicines Corp | Director | Common Stock | 0 | $0 | $128.18 | 17 Jul 2025 | Direct |
| Tango Therapeutics, Inc. | Chief Financial Officer | Stock Option (Right to Buy) | 265,980 | 02 Feb 2026 | Direct | ||
| Vor Biopharma Inc. | Director | Stock Option (Right to Buy) | 30,000 | 22 May 2025 | Direct | ||
| Upstream Bio, Inc. | Director | Stock Option (Right to Buy) | 17,096 | 10 Jun 2025 | Direct | ||
| Blueprint Medicines Corp | Director | Stock Option (Right to Buy) | 0 | 17 Jul 2025 | Direct | ||
| Translate Bio, Inc. | Director | Stock Option (right to buy) | 0 | 14 Sep 2021 | Direct |
| Symbol | Company | Period | Transactions | Value $ | Form Type | Role | Filing Time |
|---|---|---|---|---|---|---|---|
| TNGX | Tango Therapeutics, Inc. | 02 Feb 2026 | 4 | -$126,531 | 4 | Chief Financial Officer | 04 Feb 2026, 20:12 |
| BPMC | Blueprint Medicines Corp | 17 Jul 2025 | 6 | $0 | 4 | Director | 21 Jul 2025, 19:45 |
| BPMC | Blueprint Medicines Corp | 18 Jun 2025 | 1 | +$499,924 | 4 | Director | 24 Jun 2025, 16:24 |
| UPB | Upstream Bio, Inc. | 10 Jun 2025 | 1 | $0 | 4 | Director | 12 Jun 2025, 16:17 |
| VOR | Vor Biopharma Inc. | 22 May 2025 | 1 | $0 | 4 | Director | 23 May 2025, 17:45 |
| TNGX | Tango Therapeutics, Inc. | 04 Feb 2025 | 2 | -$25,282 | 4 | Chief Financial Officer | 06 Feb 2025, 20:10 |
| TNGX | Tango Therapeutics, Inc. | 03 Feb 2025 | 2 | $0 | 4 | Chief Financial Officer | 05 Feb 2025, 20:14 |
| UPB | Upstream Bio, Inc. | 10 Oct 2024 | 1 | $0 | 4 | Director | 15 Oct 2024, 16:15 |
| UPB | Upstream Bio, Inc. | 10 Oct 2024 | 0 | $0 | 3 | Director | 10 Oct 2024, 20:25 |
| BPMC | Blueprint Medicines Corp | 12 Jun 2024 | 2 | $0 | 4 | Director | 14 Jun 2024, 17:38 |
| VOR | Vor Biopharma Inc. | 23 May 2024 | 1 | $0 | 4 | Director | 28 May 2024, 16:10 |
| TNGX | Tango Therapeutics, Inc. | 06 Feb 2024 | 2 | -$46,900 | 4 | Chief Financial Officer | 08 Feb 2024, 21:08 |
| TNGX | Tango Therapeutics, Inc. | 01 Feb 2024 | 2 | $0 | 4 | Chief Financial Officer | 05 Feb 2024, 16:27 |
| BPMC | Blueprint Medicines Corp | 21 Jun 2023 | 2 | $0 | 4 | Director | 23 Jun 2023, 19:00 |
| VOR | Vor Biopharma Inc. | 26 May 2023 | 1 | $0 | 4 | Director | 02 Jun 2023, 16:33 |
| TNGX | Tango Therapeutics, Inc. | 01 Mar 2023 | 2 | $0 | 4 | Chief Financial Officer | 02 Mar 2023, 15:06 |
| BPMC | Blueprint Medicines Corp | 21 Jun 2022 | 2 | $0 | 4 | Director | 30 Jun 2022, 21:57 |
| VOR | Vor Biopharma Inc. | 14 Jun 2022 | 1 | $0 | 4 | Director | 16 Jun 2022, 17:03 |
| TNGX | Tango Therapeutics, Inc. | 01 Feb 2022 | 1 | $0 | 4 | Chief Financial Officer | 03 Feb 2022, 15:30 |
| BPMC | Blueprint Medicines Corp | 08 Dec 2021 | 2 | $0 | 4/A | Director | 31 Mar 2022, 16:05 |
| BPMC | Blueprint Medicines Corp | 08 Dec 2021 | 0 | $0 | 3/A | Director | 31 Mar 2022, 16:02 |
| /report/000120919121056038-beckman-daniella-2021-09-14 | Translate Bio, Inc. | 14 Sep 2021 | 4 | $0 | 4 | Director | 14 Sep 2021, 19:19 |
| TNGX | Tango Therapeutics, Inc. | 12 Aug 2021 | 1 | $0 | 4 | Chief Financial Officer | 16 Aug 2021, 19:00 |
| TNGX | Tango Therapeutics, Inc. | 10 Aug 2021 | 0 | $0 | 3 | Chief Financial Officer | 12 Aug 2021, 20:44 |
| /report/000120919121040993-beckman-daniella-2021-06-16 | Translate Bio, Inc. | 16 Jun 2021 | 1 | $0 | 4 | Director | 16 Jun 2021, 17:18 |